The new West Michigan center marks the ninth location in the state and the second in the region since a Kalamazoo space ...

The FDA's approval of Alhemo (concizumab-mtci) revolutionizes hemophilia treatment, offering a simpler, subcutaneous injection for better bleed control and patient independence.

Switching to the extended half-life therapy Elocta, sold in the U.S. as Eloctate, improved control of bleeds among hemophilia ...

A 26-year-old Downriver man seen at Children’s Hospital of Michigan in Detroit since infancy for a rare bleeding disorder in ...

Free blood test services are now available at the Peñarrubia Rural Health Unit (RHU) with a new hematology machine.

In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement ...

CSL Behring Italy today announced that on July 29, 2025 the Board of Directors of the Italian Medicines Agency (AIFA), approved the reimbursement of HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is ...

Jigar Kotecha, Secretary of the Hemophilia Society (Mumbai Chapter), said that a purchase order for 6,130 vials was issued on ...

There are a couple categories of conditions that can manifest with random bruising—though they typically surface with other ...

In July 2025, CSL Behring conducted a study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after ...

Medical experts share the main symptoms of Hemophilia A+B, a blood-clotting disorder. From excessive bleeding to bruising, here’s what to look out for.

The Global Coagulation Factor Deficiency Market Report (2025-2035) highlights advances in treatment options for blood clotting disorders like Hemophilia A, Hemophilia B, and Von Willebrand Disease.